The adjustment in price target by Needham reflects a slight change in valuation expectations for CRISPR Therapeutics, likely due to updated analysis or market conditions. However, maintaining a Buy rating indicates a continued positive outlook on the company's fundamentals and growth prospects. This could lead to a neutral short-term impact on the stock as the market digests the slight price target reduction against the backdrop of ongoing analyst confidence.